Literature DB >> 16263104

Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice.

Ashima Saxena1, Wei Sun, Chunyuan Luo, Bhupendra P Doctor.   

Abstract

The use of exogenously administered cholinesterases (ChEs) as bioscavengers of highly toxic organophosphate (OP) nerve agents is now sufficiently well documented to make them a highly viable prophylactic treatment against this potential threat. Of the ChEs evaluated so far, human serum butyrylcholinesterase (HuBChE) is most suitable for human use. A dose of 200 mg (3 mg/kg) of HuBChE is envisioned as a prophylactic treatment in humans that can protect from an exposure of up to 2 x LD50 of soman. In addition to its use as a prophylactic for a variety of wartime scenarios, including covert actions, it also has potential use for first responders (civilians) reacting to terrorist nerve gas release. We recently, developed a procedure for the large-scale purification of HuBChE, which yielded approximately 6 g of highly purified enzyme from 120 kg of Cohn fraction IV-4. The enzyme had a specific activity of 700-750 U/mg and migrated as a single band on SDS-PAGE. To provide data for initiating an investigational new drug (IND) application for the use of this enzyme as a bioscavenger in humans, we established its pharmacokinetic properties, examined its safety in mice, and evaluated its shelf life at various temperatures. In mice administered various doses up to 90 mg/kg, enzyme activity reached peak levels in circulation at 10 and 24 h following i.p. and i.m. injections, respectively. The enzyme displayed a mean residence time (MRT) of 40-50 h, regardless of the route of administration or dose of injected enzyme. Mice were euthanized 2 weeks following enzyme administration and tissues were examined grossly or microscopically for possible toxic effects. Results suggest that HuBChE does not exhibit any toxicity in mice as measured by general observation, serum chemistry, hematology, gross or histologic tissue changes. The shelf life of this enzyme stored at 4, 25, 37, and 45 degrees C was determined in lyophilized form. The enzyme was found to be stable when stored in lyophilized form at -20, 4, 25, or 37 degrees C to date (2 years), as measured by specific activity and SDS polyacrylamide gel electrophoresis. The effect of storage on circulatory stability was determined by measuring MRT in mice; there was no change in the MRT of lyophilized enzyme stored at -20 degrees C to date (2 years). These results provide convincing data that HuBChE is a safe bioscavenger that can provide protection against all OP nerve agents. Efforts are now underway to prepare the required documentation for submission of an IND application to the United States Food and Drug Administration (USFDA).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263104     DOI: 10.1016/j.cbi.2005.10.028

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  15 in total

Review 1.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

3.  Substrate selectivity of high-activity mutants of human butyrylcholinesterase.

Authors:  Shurong Hou; Liu Xue; Wenchao Yang; Lei Fang; Fang Zheng; Chang-Guo Zhan
Journal:  Org Biomol Chem       Date:  2013-11-21       Impact factor: 3.876

Review 4.  Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users.

Authors:  Stephen Brimijoin
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

5.  Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase.

Authors:  Xiabin Chen; Xiaoqin Huang; Liyi Geng; Liu Xue; Shurong Hou; Xirong Zheng; Stephen Brimijoin; Fang Zheng; Chang-Guo Zhan
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

Review 6.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

7.  Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Authors:  Noel D Johnson; Ellen G Duysen; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2009-03-20       Impact factor: 4.294

8.  What's new in emergencies, trauma, and shock? Snake envenomation and organophosphate poisoning in the emergency department.

Authors:  Praveen Aggarwal; Nayer Jamshed
Journal:  J Emerg Trauma Shock       Date:  2008-07

9.  Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice.

Authors:  Vishakantha Murthy; Yang Gao; Liyi Geng; Nathan K LeBrasseur; Thomas A White; Robin J Parks; Stephen Brimijoin
Journal:  Vaccine       Date:  2014-06-02       Impact factor: 3.641

10.  Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice.

Authors:  Vishakantha Murthy; Yang Gao; Liyi Geng; Nathan LeBrasseur; Thomas White; Stephen Brimijoin
Journal:  J Mol Neurosci       Date:  2013-10-02       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.